-- Zhejiang Medicine (SHA:600216) posted 2025 attributable net profit of 873.4 million yuan, down 25% from 1.16 billion yuan the previous year.
Earnings per share declined to 0.91 yuan from 1.21 yuan, according to a filing with the Shanghai bourse.
Operating revenue slid 5.3% year over year to 8.88 billion yuan from 9.38 billion yuan.
Shares of the pharmaceutical company were down 3% in recent trade.